NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Novartis
»13/11/2009 [Company watch]
Novartis to acquire majority stake in HTDS Chinese subsidiary

Hard To Treat Diseases has announced that Novartis is acquiring an 85 percent stake in HTDS\' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical, for $125 million.

 
Hard To Treat Diseases has announced that Novartis is acquiring an 85 percent stake in HTDS\' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical, for $125 million. Novartis will begin a five-year, $1 billion China initiative with two aims: the company is said to dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. HTDS\' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA. Mr Terry Yuan, HTDS\' President said \"We believe that when you start to appreciate what Novartis\' commitment to our partner in China fully means, and the see the large financial commitment to our partner just for the China market, you can begin to appreciate the enormous value to HTDS of our exclusive international marketing and sales relationship with Zhejiang Tianyuan Bio-Pharmaceutical. “As Mellow Hope owns all of registrations, clinical trials and brands for Zhejiang Tianyuan\'s international markets, the new Novartis-Zhejiang-Tianyuan entity will continue to leverage our assets and expertise in its international market. HTDS management is very optimistic and foresees its relationship and business with Zhejiang Tianyuan will only be further strengthened by the participation of Novartis.” Zhejiang Tianyuan is a privately-held vaccines company providing a competitive product portfolio and pipeline in China, where Novartis has a limited vaccines presence. Tianyuan and Novartis are to collaborate on building a vaccines industry leader targeting unmet medical needs in China, the world\'s third-largest vaccines market. Tianyuan has been delivering dynamic and profitable growth, having more than doubled its net sales to approximately $25 million in 2008.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.